Figure 6.

SNS01-T synergizes with bortezomib (Bort) to induce cytotoxicity and inhibit multiple myeloma (MM) tumor growth. (a) RPMI 8226 cells were treated with increasing doses of SNS01-T and Bort at a constant ratio of 1:1.25 for 48 hours. Cytotoxicity was measured by XTT, and synergy was determined using CompuSyn software. Mean ± SEM is shown (n = 3); an asterisk indicates P values ≤ 0.05 (two-way analysis of variance (ANOVA), Bonferroni posttest) compared with Bort, and a yen symbol indicates P values ≤ 0.05 compared with SNS01-T. S, SNS01-T; B, Bort. (b) Effect of SNS01-T, Bort, or both on the growth of RPMI 8226 xenografts. Error bars represent the SEM; asterisks indicate P values < 0.05 (one-way ANOVA, Bonferroni posttest; n = 5). Ctl nano, control nanoparticle. (c) Western blot analysis of RPMI 8226 cells after single or combination treatments of SNS01-T and Bort for 48 hours. RPMI, Roswell Park Memorial Institute.